SILO PHARMA, INC. Gain (Loss) on Extinguishment of Debt
SILO PHARMA, INC. (SILO) reported Gain (Loss) on Extinguishment of Debt of $91.64 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2026-08-13
- SILO PHARMA, INC. gain (loss) on extinguishment of debt for the quarter ending 2026-06-30 was $91.64K.
- SILO PHARMA, INC. gain (loss) on extinguishment of debt for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- SILO PHARMA, INC. gain (loss) on extinguishment of debt for the quarter ending 2021-09-30 was $0.00.
- SILO PHARMA, INC. gain (loss) on extinguishment of debt for the quarter ending 2021-06-30 was $19.08K.
- SILO PHARMA, INC. gain (loss) on extinguishment of debt for fiscal 2021 was $19.08K.
- SILO PHARMA, INC. gain (loss) on extinguishment of debt for fiscal 2020 was -$197.68K.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $91.64K 10-Q · filed 2026-08-13 | $91.64K 10-Q · filed 2026-08-13 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $0.00 derived: sum of 2 quarters · filed 2023-03-24 | $19.08K derived: sum of 3 quarters · filed 2023-03-24 | $19.08K 10-K · filed 2023-03-24 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $19.08K derived: sum of 2 quarters · filed 2022-11-10 | $19.08K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $19.08K 10-Q · filed 2022-08-01 | $19.08K 10-Q · filed 2022-08-01 | ||
| 2020-12-31 | $318.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $318.00 derived: sum of 2 quarters · filed 2022-03-28 | -$197.68K derived: sum of 3 quarters · filed 2022-03-28 | -$197.68K 10-K · filed 2022-03-28 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$198.00K derived: sum of 2 quarters · filed 2021-11-10 | -$198.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$198.00K 10-Q · filed 2021-08-13 | -$198.00K 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | -$82.50K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |